Jason M. Broderick

The approval of carfilzomib (Kyprolis) was recently expanded by the FDA to include relapsed multiple myeloma patients who have received at least one to three previous lines of therapy.

An independent panel has halted the phase III CheckMate-025 trial after determining that nivolumab (Opdivo) improved overall survival versus everolimus (Afinitor) in patients with advanced renal cell carcinoma.

Frontline nivolumab more than doubled progression-free survival (PFS), both as monotherapy and combined with ipilimumab compared with ipilimumab alone in patients with advanced melanoma, according to results from the phase III CheckMate-067 trial.

Nivolumab (Opdivo) improved overall survival and was less toxic compared with docetaxel in chemotherapy-pretreated patients with nonsquamous non–small cell lung cancer.

Adding palbociclib to standard fulvestrant more than doubled progression-free survival in pretreated patients who have HR-positive, HER2-negative breast cancer.

Treatment with elotuzumab in combination lenalidomide and dexamethasone prolonged remission by 4.5 months in patients with relapsed or refractory multiple myeloma when compared with lenalidomide and dexamethasone alone.

The PD-1 inhibitor nivolumab (Opdivo) has been has been assigned priority review designation from the US Food and Drug Administration (FDA) as a treatment for previously untreated patients with unresectable or metastatic melanoma.

Pembrolizumab (Keytruda) achieved an overall response rate (ORR) of 45.2% among a cohort of patients with high PD-L1-expressing non–small cell lung cancer (NSCLC) in the phase I KEYNOTE-001 trial.

The PALOMA-3 trial examining a palbociclib regimen in HR+/HER2- breast cancer was halted after an independent panel determined it met the primary endpoint of improving progression-free survival (PFS).

Tumor genome profiling identifies driver mutations in breast tumors, however, it is still too early to use this information in clinical decision making, according to Hope S. Rugo, MD.

The FDA has approved nivolumab (Opdivo) for the treatment of patients with advanced non-small cell lung cancer (NSCLC). The approval comes 3 months ahead of the FDA’s scheduled decision date.

Carfilzomib (Kyprolis) doubled progression-free survival (PFS) versus bortezomib (Velcade) in patients with relapsed multiple myeloma in the phase III ENDEAVOR trial.

Nivolumab (Opdivo) has been granted a priority review for use in patients with previously treated, advanced, squamous non–small cell lung cancer (NSCLC).

The MEK inhibitor cobimetinib has received an FDA priority review for use in combination with the BRAF inhibitor vemurafenib (Zelboraf) to treat patients with BRAF V600–positive advanced melanoma.

Ibrutinib (Imbruvica) showed promising activity in heavily pretreated, relapsed/refractory chronic lymphocytic leukemia (CLL) after allogeneic stem cell transplantation (ASCT).

Lenalidomide (Revlimid) plus dexamethasone has been approved by the FDA for the treatment of newly diagnosed patients with multiple myeloma who are not candidates for stem cell transplant, based on findings from the phase III FIRST trial.

The oral multikinase inhibitor motesanib failed to meet the primary endpoint of improving progression-free survival (PFS) in patients with non–small cell lung cancer (NSCLC) in the phase III MONET-A trial.

The FDA has approved lenvatinib (Lenvima) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).

Genentech, the manufacturer of obinutuzumab, plans to file for FDA and EMA approval after a phase III study of the anti-CD20 agent in indolent non-Hodgkin lymphoma (iNHL) garnered positive results in an interim analysis.

The anti–PD-L1 agent MPDL3280A has received a breakthrough therapy designation from the FDA as a potential treatment for patients with PD-L1–positive NSCLC who have progressed on platinum-based chemotherapy and a EGFR or ALK inhibitor.

The FDA has granted a Fast Track Designation to CPX-351, a liposomal formulation of cytarabine and daunorubicin, for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).

ASCO named the improved outlook for patients with chronic lymphocytic leukemia (CLL) as its inaugural “Cancer Advance of the Year.”

Second-line treatment with the VEGFR2 inhibitor ramucirumab (Cyramza) combined with standard FOLFIRI extended survival by 1.6 months versus FOLFIRI alone in patients with metastatic colorectal cancer (mCRC).

Nivolumab (Opdivo) improved survival compared with docetaxel in patients with pretreated squamous cell non–small cell lung cancer (NSCLC) in the phase III CheckMate-017 trial, according to Bristol-Myers Squibb (BMS), which manufactures the drug.

In a unanimous 14-0 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended the approval of EP2006, a biosimilar version of filgrastim (Neupogen; Amgen).

Frontline treatment with everolimus (Afinitor) combined with trastuzumab (Herceptin) and paclitaxel failed to delay disease progression versus trastuzumab and paclitaxel alone in patients with HER2-positive advanced breast cancer.

Women with HR+ breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or—to a lesser extent—tamoxifen, compared with standard tamoxifen alone.

Women with HER2-positive breast cancer and high levels of stromal tumor-infiltrating lymphocytes (S-TILs) treated with chemotherapy alone had an 80% lower likelihood of disease recurrence compared to those with lower TIL counts.

Both HPV-positive and -negative head and neck cancers are “outstanding candidates for immunotherapeutic strategies,” said Andrew G. Sikora, MD, PhD, Baylor College of Medicine, at the 2014 Chemotherapy Foundation Symposium.

The landscape in lymphoma management continues to evolve, with new therapies and approaches improving established treatment paradigms.